Latest Conference Articles

After maintenance treatment with sonelokimab dosed every 4 weeks, 57% of patients achieved HiSCR75 at week 24.

Overall, acne events were mild or moderate and did not cause patients to discontinue ruxolitinib cream treatment.

The continued reduction in WI-NRS was seen in patients who remained in the study through week 52.

UCB presented data from the BE HEARD I and BE HEARD II phase 3 studies at this year's EADV Congress.

Sanofi’s phase 3 program for amlitelimab in atopic dermatitis will start in early 2024.

Almirall presented new data on lebrikizumab at EADV related to clinical improvements and clinically-meaningful treatment responses among patients with atopic dermatitis.

At week 8, 65.3% of roflumilast-treated patients achieved a clinically significant reduction in itch.

AbbVie announced the 24- and 52-week data at EADV 2023.

Patients and their families experienced significant improvements to well-being with tildrakizumab use in as little as 16 weeks.

Longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation.

Clinical response was maintained at 73.2% for PASI-75 in POETYK PSO long-term extension trial.

Kristina Collins, MD, delves into the importance of being present in the moments you have control over and making self-care a priority on the road.

Discover the top pearls and takeaways from sessions at Maui Derm NP+PA Fall 2023 in Asheville, North Carolina.

New and emerging therapies to treat a variety of skin conditions were presented by George Martin, MD, and Ted Rosen, MD.

The hair guru explains how he opened up the first dermatology practice dedicated to hair, pearls from his session, innovative therapies, and research he has recently submitted.

Colleen Cotton, MD, does a deep dive on pediatric atopic dermatitis and explains the importance of timing and conversations with patients about different treatments.

Trifarotene emerges as an effective and well-tolerated solution for acne across diverse populations.

The distribution of eyebrow and eyelash hair loss in relation to the severity of scalp hair loss remains underexplored, and this study established baseline characteristics.

Matthew Zirwas, MD, addressed solutions to the toll consistent handwashing, sanitizing, and wearing gloves can take on hands.

Researchers found that continued use of once-daily subantibiotic dose oral doxycycline 40 mg modified-release capsules significantly reduced the relapse rate and inflammatory lesion counts in patients with moderate-to-severe rosacea.

We had the chance to catch up with Serrao before he took the stage and he explained why dermatology clinicians should keep their eyes on bimekizumab’s data and shared opportunities for further research.

In a Q&A, she shares pearls from her personal experiences treating pediatric acne and other underlying conditions that may require a multidisciplinary plan.

The intense itching associated with prurigo nodularis significantly affects patients’ quality of life, leading to higher rates of anxiety, depression, and sleep disturbances.

Leaders in dermatology shared a review of thought-provoking literature published this year to consider in practice, diagnostic solutions, and treatment strategies.

The phase 3 trial of once-daily roflumilast foam has shown promising results in the treatment of seborrheic dermatitis.

A poster session at Maui Derm NP+PA Fall delves into data surrounding the use of olive oil in therapeutic applications.

He delves into one of his most challenging recent cases, the evolution of treatment options, and strategies to think outside of the box in diagnostic and therapeutic approaches.

She shares her top 5 considerations for all dermatology drug prescribers.